83 related articles for article (PubMed ID: 9576195)
1. Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts.
Vitale A; Guarini A; Latagliata R; Cignetti A; Foa R
Br J Haematol; 1998 Apr; 101(1):150-7. PubMed ID: 9576195
[TBL] [Abstract][Full Text] [Related]
2. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
Torelli GF; Guarini A; Palmieri G; Breccia M; Vitale A; Santoni A; Foa R
Br J Haematol; 2002 Feb; 116(2):299-307. PubMed ID: 11841430
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
[TBL] [Abstract][Full Text] [Related]
4. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
[TBL] [Abstract][Full Text] [Related]
5. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
Linn YC; Lau LC; Hui KM
Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399
[TBL] [Abstract][Full Text] [Related]
6. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
7. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
Roddie PH; Horton Y; Turner ML
Leukemia; 2002 Jan; 16(1):84-93. PubMed ID: 11840267
[TBL] [Abstract][Full Text] [Related]
8. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
Brune M; Hellstrand K
Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
[TBL] [Abstract][Full Text] [Related]
9. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
[TBL] [Abstract][Full Text] [Related]
10. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.
Hardwick N; Chan L; Ingram W; Mufti G; Farzaneh F
Cancer Immunol Immunother; 2010 Mar; 59(3):379-88. PubMed ID: 19711075
[TBL] [Abstract][Full Text] [Related]
11. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.
Kaneko T; Fusauch Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Leuk Lymphoma; 1994 Jul; 14(3-4):219-29. PubMed ID: 7950910
[TBL] [Abstract][Full Text] [Related]
13. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
Archimbaud E; Bailly M; Doré JF
Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
[TBL] [Abstract][Full Text] [Related]
15. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.
Rossi FM; Degan M; Mazzocco FT; Di Francia R; Aldinucci D; Poletto D; Vellenga E; Pinto A; Gattei V
Br J Haematol; 2002 Apr; 117(1):59-69. PubMed ID: 11918534
[TBL] [Abstract][Full Text] [Related]
18. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex-vivo generation of CTL for immunotherapy.
Orleans-Lindsay JK; Deru A; Craig JI; Prentice HG; Lowdell MW
Clin Exp Immunol; 2003 Sep; 133(3):467-75. PubMed ID: 12930376
[TBL] [Abstract][Full Text] [Related]
19. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]